65,437 trials
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (Complete Response/Partial Response) — 0 percentage of participants
Total Knee Replacement Surgery
Primary: Pain Numerical Rating Scale — 6.38; 5.31 score on a scale
Neuroblastoma Recurrent
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 1; 3 Participants
Refractive Errors
Primary: Subjects With Stable Manifest Refraction Spherical Equivalent (MRSE) — 7 Subjects
Solid Tumors · Cancer
Primary: Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only — 4.7; 5.2; 10; 0 percentage of participants
Otitis Media · Infections, Respiratory Tract · Respiratory Tract Infections
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 10; 3; 3 Participants
Polybrominated Biphenyl Poisoning
Primary: Weight — 91.3; 92.3; 88.6; 87.4 kilograms (kg)
PH1 · Primary Hyperoxaluria · RNAi Therapeutic
Primary: Number of Participants With at Least One Adverse Event (AE) — 13; 7 Participants
Alcohol Drinking · Craving
Primary: Alcohol Craving — 2.51; 2.79 units on a scale
Diabetic Macular Edema
Primary: Mean Change in Visual Acuity — 15; 14 Letter Score
Temple Hollowing
Primary: Percentage of Participants With ≥ 1-grade Improvement From Baseline in the Validated Allergan Temple Hollowing Scale (ATHS) Based on Evaluating Investigator (EI)…
BPH · Prostate Hyperplasia · Urinary Frequency/Urgency
Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale
Glioma
Primary: Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) — 0; 2; 0; 1 Participants
Ischemia
Primary: Wound Healing — 30 Participants